Paris – October 15, 2026 -- Biomemory has launched DNA Shield, a managed service that stores encrypted customer data as synthetic DNA in offline custody, and opened its Early Access Program to organizations that need an independent layer for critical digital assets. It is the company's first commercial product.
The service is built as a separate layer held at rest, apart from the active control plane and outside the network-reachable attack surface. Biomemory pitches it at information that must stay trustworthy for years or decades, including against risks from advances in artificial intelligence and quantum computing.
Biomemory acquired Catalog's assets in March and named Laurent Guengant CEO in July
In March 2026, Biomemory acquired the assets of Boston-based Catalog Technologies, a DNA data storage and computing pioneer. The deal gave Biomemory a second production and research hub in Boston alongside its Paris headquarters, and expanded its intellectual property position.
In July 2026, the company appointed Guengant, an executive with more than 30 years in storage, telecom and energy, as CEO. The appointment moves Biomemory from research toward industrialization and commercial deployment.
DNA Shield encodes encrypted customer data into DNA under managed custody
Customers first select and encrypt the material in scope during secure onboarding. DNA Shield then encodes it into synthetic DNA held offline. Recovery is a controlled process triggered deliberately when needed, not routine or self-service access.
The service targets cryptographic keys, proprietary industrial knowledge, regulated records and institutional memory. Biomemory lists four initial use cases:
- Key custody continuity, designed to complement a certified HSM rather than replace one.
- Offline, sovereign copies of crown jewel industrial IP, such as proprietary formulations, processes or design parameters.
- Tamper-evident copies of regulated records, proving they have not been altered since approval.
- Sovereign memory and golden records for institutions preserving records that must outlast the systems and organizations that created them.
More use cases will be added as the Early Access Program grows.
Management frames the launch as a shift from research to commercial product
Guengant called DNA Shield "the moment Biomemory moves from proving a science to delivering a commercial product." He described it as the first step on a roadmap from sovereign data protection into storage, molecular search and compute.
Vincent Franceschini, Vice President of Product Management and co-chair of the DNA Data Storage Alliance, said it is the first time Biomemory is asking a customer to rely on its molecular platform operationally rather than as a research demonstration. DNA Shield is the first product in what the company calls Molecular IT, with further details promised in future announcements. Biomemory's roadmap places DNA storage from 2029, with molecular search and compute beyond that.